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stratified as to presence or absence of CKD G3a (estimated 
glomerular filtration rate [eGFR] 45–59 mL/min/1.73 m 2 vs. 
eGFR  ≥ 60 mL/min/1.73 m 2 ). GA comprised the following in-
struments: the Activities of Daily Living Scale (ADL), the 
Timed up and Go (TUG), the Tinetti test (Tinetti), the Mini-
Mental-State Examination (MMSE), the Geriatric Depression 
Scale (GDS), and the Mini Nutritional Assessment (MNA). We 
used logistic regression models to estimate multivariable-
adjusted associations between CKD G3a and impairments in 
the respective domains.  Results: A total of 282 subjects with 
mild-to-moderate CKD (CKD G3a) were identified (19.1%). 
Overall, the prevalence of impairments identified was higher 
among subjects with compared to without CKD G3a (21 vs. 
15.9%,  p = 0.043). In multivariable-adjusted models, CKD G3a 
was consistently associated with increased odds of an im-
paired gait performance as to the TUG (adjusted odds ratio 
2.06, 95% CI 1.04–4.09). In contrast, on average, individuals 
with and without CKD G3a did not differ as to their results in 
the MMSE, the ADL, the MNA, and the GDS.  Conclusion: GA 
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 Abstract 
 Background: Mild-to-moderate chronic kidney disease (CKD 
G3a) is prevalent in older adults. Substantial evidence sug-
gests that individuals with advanced CKD face a high risk for 
common geriatric conditions, like functional impairment 
and cognitive decline, whereas the relationships between 
mild-to-moderate CKD and functional impairment and cog-
nitive decline, but also poor nutritional status and mood dis-
orders, are still unclear.  Objective: The aim of this study was 
to explore associations between mild-to-moderate CKD and 
impairments in the core domains of geriatric assessment 
(GA) in a large cohort of community-dwelling older adults. 
 Methods: This was a cross-sectional analysis of 1,476 par-
ticipants of the Berlin Aging Study II. Study participants were 
 Received: June 13, 2017 
 Accepted: October 11, 2017 
 Published online: November 29, 2017 
 Maximilian König, MD 
 Charité – Universitätsmedizin Berlin 
 Augustenburger Platz 1  
 DE–13353 Berlin (Germany) 
 E-Mail koenig.maximilian   @   charite.de 
 © 2017 S. Karger AG, Basel 
 www.karger.com/ger 
 Geriatric Assessment in 
Mild-to-Moderate CKD 
Gerontology 2018;64:118–126
DOI: 10.1159/000484140
119
identified impairments in 21 versus 15.9% of older adults 
with and without mild-to-moderate CKD, respectively. How-
ever, except for an increased likelihood of impaired gait per-
formance (TUG) with mild-to-moderate CKD, we did not find 
independent associations between mild-to-moderate CKD 
and geriatric conditions.  © 2017 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) affects large propor-
tions of older adults. Reduced kidney function is associ-
ated with an increased risk of unsuccessful aging and ad-
verse clinical outcomes, e.g. cardiovascular events, hos-
pitalizations, and death  [1–6] . Moreover, substantial 
evidence suggests that individuals with CKD face a high 
risk for common geriatric conditions, like functional im-
pairment and cognitive decline  [3] .
 The vast majority of individuals with CKD only show 
mild-to-moderately decreased glomerular filtration rate 
(GFR 45–59 mL/min/1.73 m 2 )  [5] . There is an ongoing 
debate about the clinical significance of early-stage CKD 
among older adults, and whether the universal GFR 
threshold for the definition of CKD (< 60 mL/min/1.73 
m 2 ), as proposed by the KDIGO (Kidney Disease/Im-
proving Global Outcomes), is applicable in older adults, 
or should be lower (e.g., <45 mL/min/1.73 m 2 ) in view of 
the age-related decline in renal function  [3, 7, 8] .
 In this context, it is not only important to consider the 
implications of mild-to-moderately decreased GFR for 
cardiovascular risk and renal disease progression, but also 
to consider functional status, mental health, nutritional 
status, and cognition.
 In fact, previous studies have mainly shown a high 
prevalence and incidence of functional impairment and 
cognitive decline in older adults with  advanced CKD (es-
timated GFR [eGFR] <45 mL/min/1.73 m 2 ) and dialysis 
patients, but to date only few studies have examined func-
tional and cognitive impairments in older adults with 
only  mild-to-moderate CKD (GFR 45–59 mL/min/1.73 
m 2 , CKD G3a)  [3, 9–11] .
 Geriatric conditions, including medical, psychosocial, 
and functional limitations, can best be identified by a ge-
riatric assessment (GA). GA uses established diagnostic 
tools to identify geriatric conditions otherwise often not 
identified in routine history or physical examination. In 
addition to its routine use in clinical geriatrics, following 
calls for a widespread use, GAs have also been incorpo-
rated step by step into the practice of various medical sub-
specialties, such as oncology, surgery, and nephrology  [3, 
12–14] . Common and established tests of the GA are the 
Activities of Daily Living Scale (ADL), the Timed Up and 
Go (TUG) and the Tinetti test, both testing gait perfor-
mance and mobility, the Mini-Mental State Examination 
(MMSE) as a screening test for cognitive impairments, 
the Geriatric Depression Scale (GDS), and the Mini Nu-
tritional Assessment (MNA)  [15, 16] .
 The aim of the present study was to explore associa-
tions between mild-to-moderate CKD (G3a) and preva-
lent impairments, identified by GA in cross-sectional 
data of a large cohort of community-dwelling older adults. 
We hypothesized that GA would identify significantly 
more impairments in subjects with CKD G3a compared 
to subjects with preserved kidney function (eGFR  ≥ 60 
mL/min/1.73 m 2 ). This, in turn, would support the clini-
cal relevance of mild-to-moderate CKD.
 Methods 
 Study Sample 
 Altogether 1,476 participants (mean age: 68.6 ± 3.6 years) from 
the Berlin Aging Study II (BASE-II) were included in this cross-
sectional analysis. BASE-II was launched to investigate factors as-
sociated with “healthy” and “unhealthy” aging. The study has been 
described previously in detail  [17, 18] . Briefly, the BASE-II sample 
was recruited as a convenience sample from the greater Berlin met-
ropolitan area. In 2009–2014, 2,172 participants ( ∼ 75% aged 60–
84 years and  ∼ 25% aged 20–35 years) were enrolled in the medical 
part of the study. All participants gave written informed consent 
and the study was approved by Ethics Committee at Charité-Uni-
versitätsmedizin Berlin (EA2/029/09). Data sets including all rel-
evant variables for the present analysis were available from 1,498 
participants of the older group of BASE-II (aged 60 years and old-
er). We a priori excluded participants with eGFR <45 mL/min/1.73 
m 2 ( n = 22), as we intended to study mild-to-moderate CKD 
(eGFR 45–59 mL/min/1.73 m 2 ). Thus, analyses were limited to 
1,476 subjects.
 Geriatric Assessment 
 GA comprised the following instruments (see also  Table 1 ).
 Tinetti Test 
 The Tinetti test, also known as Performance Oriented Mobility 
Assessment (POMA), is the most widely used clinical test for as-
sessing a person’s static balance abilities and gait. The maximum 
achievable score is 28. A score of  ≤ 23 was rated as an impairment 
in this test  [19] .
 Timed Up and Go  
 The TUG is a commonly used screening tool for mobility and 
falls. A faster time indicates a better gait performance (stand up, 
walk, turn, sit down). In accordance with the previous literature 
 [20] a time of >12 s was rated as impairment, indicating impaired 
gait performance.
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 Activities of Daily Living 
 The ADL, also known as Barthel index, is used to measure a 
person’s ability to perform basic daily self-care tasks. A higher score 
(max. 100) is associated with a greater likelihood of being able to 
live at home without problems  [21] . A score of <95 was rated as 
impairment, indicating difficulty in one or more ADL tasks.
 Mini Nutritional Assessment  
 The MNA is a validated nutrition screening and assessment 
tool (maximum achievable score 30). It comprises 18 questions 
from four categories: anthropometric assessment, general state, di-
etary assessment and self-assessment. It identifies geriatric pa-
tients who are malnourished (score <17) or at risk of malnutrition 
(score  ≤ 23.5)  [16, 22] . We used  ≤ />23.5 as cutoff for classification 
into poor and normal nutritional status, respectively.
 Geriatric Depression Scale  
 The GDS is a simple, 15-item, self-report instrument used to 
identify clinical depression among elderly people. In BASE-II, a 
physician read the items of the questionnaire to the participants 
during a structured interview. Higher scores indicate more symp-
toms of depression. In line with previous studies, we rated scores 
>5 as impairment  [23, 24] .
 Mini-Mental State Examination  
 The MMSE measures global cognitive function. The total score 
for the MMSE ranges from 0 to 30. Scores >24 indicate basically 
no cognitive impairment, whereas scores  ≤ 24 may indicate cogni-
tive impairment  [25] . In BASE-II, a trained physician adminis-
tered the MMSE, and scores  ≤ 24 were rated as cognitive impair-
ment.
 Kidney Function 
 Serum creatinine levels were measured in a certified central lab-
oratory by a compensated Jaffe assay, traceable to IDMS (Roche Di-
agnostics, Mannheim, Germany). eGFR was calculated according to 
the FAS (Full Age Spectrum) equation based on serum creatinine, 
age, and weight  [26] . Urinary albumin and creatinine excretion were 
quantified from spot urine samples, and albumin/creatinine ratio 
(ACR) was calculated. Albuminuria was defined as an ACR  ≥ 30 
mg/g. Subjects were classified into GFR stages (G1–G5) and albu-
minuria categories (A1–A3) according to the KDIGO (Kidney dis-
ease improving global outcomes) guidelines  [3] . Stage G3a indicates 
mild-to-moderate CKD (GFR 45–59 mL/min/1.73 m 2 ).
 Other Study Variables 
 We computed a morbidity index (MI), largely based on the 
categories of the Charlson index, which is a weighted sum of mod-
erate to severe, mostly chronic physical illnesses, including can-
cer, cardiovascular, and metabolic diseases  [27] . Diagnoses were 
obtained by integration of information from medical examina-
tion, medical history, and further diagnostics such as laboratory 
tests (for details, see Bertram et al.  [17] ). The MI had a range of 
0–10.
 All blood and urine parameters were measured in a central cer-
tified laboratory using standardized protocols, as previously de-
scribed  [4] . Vitamin D deficiency was defined as a 25(OH)D con-
centration of <50 nmol/L. Anemia was defined according to the 
WHO criteria  [28] as a hemoglobin concentration lower than 12 
g/dL in women and 13 g/dL in men. Handgrip strength was mea-
sured with a Smedley Dynamometer (Scandidact, Denmark), and 
reduced hand grip was defined according to the cutoffs proposed 
by Fried et al.  [29] . Subjects were considered physically inactive if 
they had affirmed the statement “I rarely or never do any physical 
activities.”
 Statistics 
 Performance in the GA was compared between subjects with 
eGFR 45–59 mL/min/1.73 m 2 (CKD G3a, mild-to-moderate 
CKD) and those with eGFR  ≥ 60 mL/min/1.73 m 2 (preserved kid-
ney function). Values are expressed as counts and percentages or 
mean ± standard deviation or median and 10–90 percentiles, re-
spectively.
 Multiple logistic regression models were computed to estimate 
multivariable-adjusted associations of CKD G3a (eGFR 45–59 
mL/min/1.73 m 2 vs. eGFR  ≥ 60 mL/min/1.73 m 2 as reference 
group) with the performances in the various tests. Test outcomes 
were dichotomized according to validated thresholds, defining im-
pairment (see above). Those covariates were included in the final 
model, which showed significant differences in univariate analyses 
( Table 2 ): age, sex, BMI, MI count, vitamin D deficiency, and cur-
rent smoking. We performed additional regression analyses with 
albuminuria (ACR  ≥ 30 mg/g) as another covariate, and we tested 
an alternative definition of CKD, including GFR and albuminuria 
(GFR 45–59 mL/min/1.73 m 2 or GFR  ≥ 60 mL/min/1.73 m 2 and 
ACR  ≥ 30 mg/g), respectively.
 Likewise, effect modification by sex was assessed by including 
an interaction term for CKD G3a and sex. Statistical significance 
was evaluated at  p < 0.05. We used IBM SPSS Statistics version 23.
 Table 1.  Overview of instruments, domains, scoring and cutoffs used
Instrument Domain Scoring Cutoff for impairment Ref.
TUG gait, mobility time (s) >12 s [20]
Tinetti balance and gait 0 – 28 points ≤23 points [19]
ADL (Barthel index) functioning 0 – 100 points <95 points [21]
MNA nutrition 0 – 30 points ≤23.5 points [16, 22]
GDS depression 0 – 15 points >5 points [23, 24]
MMSE cognition 0 – 30 points ≤24 points [25]
TUG, Timed Up and Go; ADL, Activities of Daily Living Scale; MNA, Mini Nutritional Assessment; GDS, 
Geriatric Depression Scale; MMSE, Mini-Mental State Examination; 
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 Results 
 Table  2 shows the participant characteristics ( n = 
1,476). The mean age was 68.6 ± 3.6 years, 51.3% were 
female. The mean eGFR was 69.4 ± 10.7 mL/min/1.73 m 2 
(range 45.2–104.6 mL/min/1.73 m 2 ). 282 subjects (19.1%) 
had CKD stage 3a (eGFR of 45–59 mL/min/1.73 m 2 ).
 Subjects with CKD G3a were slightly older (70.5 ± 3.7 
vs. 68.1 ± 3.5 years,  p < 0.001) compared to participants 
with preserved kidney function (eGFR  ≥ 60 mL/min/1.73 
m 2 ). The average eGFR was 54.8 ± 3.9 and 72.9 ± 8.7 mL/
min/1.73 m 2 , respectively. More people with CKD G3a 
likewise had albuminuria (11.2 vs. 7.2%,  p = 0.033).
 On average, participants with CKD G3a had a higher 
MI score, and were more likely to have a MI of >3, indi-
cating multiple comorbidities, compared to those with 
preserved kidney function (9.2 vs. 4.7%,  p = 0.003). Like-
wise, the average BMI was higher among participants 
with CKD G3a. Remarkably, vitamin D deficiency was 
significantly more prevalent among subjects without 
CKD. Moreover, those without CKD G3a reported more 
often current smoking. To note, we did not find any sig-
nificant differences in the prevalence of hypertension, 
type 2 diabetes, and anemia between participants with 
and without CKD G3a, as defined by an eGFR of 45–59 
versus  ≥ 60 mL/min/1.73 m 2 ( Table 2 ).
 Association of CKD G3a and GA Outcomes 
 As shown in  Table 3 , participants with CKD G3a (eGFR 
45–59 mL/min/1.73 m 2 ) performed significantly worse in 
the TUG, compared to those with eGFR  ≥ 60 mL/min/1.73 
m 2 . On average, time to complete the TUG (stand up, 
walk, turn, sit down) differed by 0.41 s. Likewise, in the 
Tinetti, there were small but significant differences be-
tween the two groups. In contrast, participants with and 
without CKD G3a did not differ as to the results of the 
GDS, the MMSE, the ADLs, and the MNA ( Table 3 ).
 We applied validated cutoffs (see Methods and  Tables 
1  and 4 ) to the test results in order to define clinically rel-
evant impairments for each instrument. In the TUG (6.8 
vs. 2.5%,  p < 0.001) as well as in the Tinetti (3.2 vs. 1.3%, 
 p = 0.032), participants with CKD G3a were more likely 
to show impairments, compared to subjects with eGFR 
 ≥ 60 mL/min/1.73 m 2 . Proportions of participants with 
 Table 2. Characteristics of the study sample by CKD status
Total sample
(n = 1,476)
GFR
≥60 mL/min/1.73 m2
(n = 1,194)
GFR
45 – 59 mL/min/1.73 m2
(n = 282)
p
Females 757 (51.3) 595 (49.8) 162 (57.4) 0.024
Age, years 68.6±3.6 68.1 ± 3.5 70.5 ± 3.7 <0.001
Body mass index 26.7 ± 4.2 26.6 ± 4.1 27.2 ± 4.2 0.048
eGFR, mL/min/1.73 m2 69.4 ± 10.7 72.9 ± 8.7 54.8.±3.9 <0.001
ACR >30 mg/g 113 (8) 83 (11.2) 30 (7.2) 0.033
HbA1c, % 5.59 ± 0.55 5.58 ± 0.54 5.65 ± 0.59 0.080
HDL cholesterol, mg/dL 62.6 ± 17.0 62.8 ± 17.0 61.9 ± 17.1 0.400
Morbidity index 1 (0 – 3) 1 (0 – 3) 1 (0 – 3) 0.015
Morbidity index >3 82 (5.6) 58 (4.7) 26 (9.2) 0.003
Physical inactivity 130 (9.2) 103 (8.9) 27 (10.2) 0.479
Hypertensiona 1,043 (76.6) 839 (81.3) 204 (75.5) 0.098
Diabetesa 178 (12.4) 143 (12.2) 35 (13.2) 0.680
Heart failure 25 (1.8) 20 (1.8) 5 (2.0) 0.796
History of malignancy 180 (12.2) 136 (11.4) 44 (15.6) 0.068
Current smoking 138 (9.4) 124 (10.4) 14 (5.0) 0.004
Reduced handgrip 100 (7.3) 79 (7.1) 21 (8.4) 0.503
Vitamin D deficiencya 621 (43.5) 530 (46.1) 91 (33.0) <0.001
Anemiaa 87 (6.0) 65 (5.5) 22 (8.0) 0.685
 Data are presented as n (%), mean ± SD, or median (10 – 90 percentiles). Differences in proportions between 
GFR 45-59 mL/min/1.73 m2 and GFR ≥60 vs. mL/min/1.73 m2 were assessed using χ2 or Fisher’s exact test. t test 
or Mann-Whitney U test were used to assess statistical difference between continuous variables. eGFR, estimated 
glomerular filtration rate; HDL, high-density lipoprotein; CKD, chronic kidney disease; HbA1c, glycated 
hemoglobin; ACR, albumin/creatinine ratio. a Confirmed diagnoses, otherwise self-reported.
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impairments in the other tests (MMSE, GDS, MNA, 
ADLs) were similar in both groups. In sum, in about one-
fifth (21%) of participants with CKD G3a, compared to 
only 15.9% of participants without CKD, one or more im-
pairments were identified. The difference was statistically 
significant ( p = 0.043).
 As shown in  Table 2 , in addition to differences in kid-
ney function measures, the two groups differed signifi-
cantly in terms of age, sex, BMI, vitamin D deficiency and 
current smoking status, rendering further adjusted analy-
ses necessary.
 We used logistic regression analyses to estimate adjust-
ed associations of CKD G3a with impairments in the ex-
amined domains ( Table  5 ). Compared to the reference 
category (GFR  ≥ 60 mL/min/1.73 m 2 ), CKD G3a signifi-
cantly raised the odds of showing impairments in the 
TUG. This association remained statistically significant 
after we adjusted for all the above-mentioned covariates 
(adjusted odds ratio = 2.06, 95% CI 1.04–4.09). There was 
no evidence of effect modification by sex in the association 
of CKD G3a and TUG impairments ( p for interaction = 
0.279). By contrast, the association between CKD G3a and 
presence of impairments in the Tinetti was attenuated and 
did not remain statistically significant when controlling 
for confounding factors. Evidence of impairments in the 
MMSE, the MNA, the GDS, and the ADL scale was con-
sistently not statistically associated with mild-to-moder-
ate CKD in unadjusted and adjusted analyses.
 Presence of albuminuria (ACR  ≥ 30 mg/g) is another 
diagnostic criterion of CKD, independent of the evidence 
of a decreased GFR  [3] . We also considered this in our 
analyses. Admittedly, including microalbuminuria as an-
other covariate did not alter the results of the multiple 
regression analyses. Likewise, the magnitude of the asso-
ciation between CKD G3a and impaired gait performance 
(TUG) was not changed when albuminuria was added to 
the definition of mild-to-moderate CKD (adjusted odds 
ratio: 2.2, 95% CI 1.1–4.4,  p = 0.02).
 Table 4. Distribution of impairments in 6 different assessment 
instruments by CKD status
Test GFR
≥60 mL/min/1.73 m2
GFR 45 – 59
mL/min/1.73 m2
p
MNA 3.7 (44/1,192) 2.5 (7/281) 0.322
GDS 5.6 (65/1,157) 5.6 (15/267) 1.000
TUG 2.5 (30/1,194) 6.8 (19/281) 0.001
Tinetti 1.3 (15/1,179) 3.2 (9/282) 0.032
MMSE 0.8 (10/1,194) 2.1 (6/282) 0.100
ADL 2.6 (31/1,193) 3.9 (11/282) 0.237
Any test 15.9 (189/1,186) 21.0 (58/276) 0.043
Data are presented as % (n/N). χ2 or Fisher’s exact test were 
used to assess differences between the two groups GFR 45 – 59 mL/
min/1.73 m2 vs. GFR ≥60 mL/min/1.73 m2. GFR, glomerular 
filtration rate; MNA, Mini Nutritional Assessment; GDS, Geriatric 
Depression Scale; TUG, Timed Up and Go; MMSE, Mini-Mental 
State Examination; ADL, Activities of Daily Living Scale; any test, 
impairment in at least one test; CKD, chronic kidney disease. Test 
results were dichotomized, for cutoffs see Methods and Table 1.
 Table 3. Results of the geriatric assessment in the total sample and according to CKD status (GFR ≥60 vs. GFR 
45 – 59 mL/min/1.73 m2)
Total sample
(n = 1,476)
GFR ≥60 mL/min/1.73 m2
(n = 1,194)
GFR 45 – 59 mL/min/1.73 m2
(n = 282)
p
ADL score 100 (95 – 100) 100 (95 – 100) 100 (95 – 100) 0.078
Tinetti score 28 (27 – 28) 28 (27 – 28) 28 (26 – 28) <0.001
TUG, s 7.90 ± 1.90 7.82 ± 1.88 8.23 ± 1.96 0.002
MNA score 27.5 (25 – 29.5) 27.5 (25 – 29,5) 27.5 (25.5 – 29.5) 0.812
GDS score 1 (0 – 4) 1 (0 – 4) 1 (0 – 4) 0.705
MMSE score 29 (28 – 30) 29 (28 – 30) 29 (28 – 30) 0.937
Data are presented as mean ± SD or median (10 – 90 percentiles). Differences in mean ± SD or median (10 – 90 
percentiles) between the two groups GFR 45 – 59 mL/min/1.73 m2 vs. GFR ≥60 vs. mL/min/1.73 m2 were assessed 
using t test (TUG) or Mann-Whitney U test (ADL, Tinetti, MNA, GDS, MMSE), respectively. GFR, glomerular 
filtration rate; ADL, Activities of Daily Living Scale; TUG, Timed Up and Go test; MNA, Mini Nutritional 
Assessment; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination; CKD, chronic kidney 
disease.
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 Discussion 
 In this study, we investigated whether mild-to-moder-
ate CKD (CKD G3a) was associated with an increased 
prevalence of impairments in the core domains of GA, 
with consideration of gait performance (TUG/Tinetti), 
nutrition (MNA), cognition (MMSE), mood disorders 
(GDS), and independence in activities of daily living 
(ADL).
 As a result, we indeed found that the odds of showing 
impaired gait performance (TUG) were significantly 
raised for participants with CKD G3a, compared to par-
ticipants with preserved kidney function; but altogether, 
mild-to-moderate CKD was not associated with a mark-
edly increased burden of impairments. In fact, we did not 
find relevant associations between CKD G3a and restric-
tions in ADL, cognitive impairments (MMSE), depres-
sion (GDS), or abnormalities in the MNA.
 Remarkably, although in 21% of participants with 
CKD G3a GA revealed impairments in one or more do-
mains, compared to 15.9% of participants without CKD, 
prevalence of impairments in the respective domains was 
altogether rather low (<10%, respectively) in the control 
group as well as in the CKD G3a group. This is probably 
owing to the fact that the BASE-II cohort on average was 
rather young (68.6 ± 3.6 years), and participants were pre-
dominantly well functioning, as was reported before  [17] . 
Therefore, also the prevalence of kidney disease was rath-
er on the lower bound of what can normally be expected 
in the general population  [4] . In contrast, studies in older 
patients and with more advanced CKD found much high-
er prevalence rates of deficits  [13] .
 Our results support and extend beyond the findings of 
prior studies on early-stage CKD and functional status, 
cognitive impairment, mood disorders, and nutritional 
risk in older adults. As to functional status, results from 
previous studies have been inconsistent, yet altogether, 
the available evidence suggests that even early stages of 
CKD are linked with increased functional impairment. 
For example, Smyth et al.  [30] could show in 3,499 older 
adults (66.0 ± 10.3 years) that mild-to-moderate CKD 
(mean eGFR crea 50.2 mL/min/1.73 m 2 , GFR range 30–59 
mL/min/1.73 m 2 ) was positively associated with self-re-
ported functional impairment (ADLs), independent of 
age, gender, comorbidities, and cardiovascular risk fac-
tors. In the present study, we could not establish any as-
sociation between CKD G3a and limitations in ADLs. 
However, one must acknowledge that renal impairment 
was significantly less pronounced in our sample (mean 
eGFR 54.8 mL/min/1.73 m 2 , GFR range 45–59 mL/
min/1.73 m 2 ).
 Indeed, our results suggest, that CKD G3a is associated 
with increased odds of impaired gait performance, as as-
sessed by the TUG. Correspondingly, Liu et al.  [31] could 
show that mild CKD was associated with increased odds 
of incident self-reported mobility impairment and great-
er decline in gait speed (Framingham Offspring Study). 
However, this was only evident when eGFR was estimat-
ed from cystatin C instead of creatinine. This finding has 
been confirmed by a recent study by Canney et al.  [32] . In 
contrast, in the Health ABC study a positive relationship 
between mild reductions in kidney function and physical 
performance was consistently found using cystatin C or 
creatinine, respectively  [33] . Apparently, cystatin C seems 
Test Unadjusted odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)a
Adjusted odds
ratio (95% CI)b
MNA 0.67 (0.30 – 1.50) 0.71 (0.31 – 1.64) 0.70 (0.29 – 1.65)
GDS 1.0 (0.56 – 1.78) 1.09 (0.60 – 1.99) 1.02 (0.54 – 1.91)
TUG 2.81 (1.56 – 5.08) 1.99 (1.07 – 3.71) 2.06 (1.04 – 4.09)
Tinetti 2.59 (1.12 – 5.98) 2.26 (0.93 – 5.48) 1.86 (0.68 – 5.07)
MMSE 2.58 (0.93 – 7.14) 2.02 (0.69 – 5.92) 2.30 (0.74 – 7.20)
ADL 1.52 (0.76 – 3.07) 1.08 (0.51 – 2.27) 0.84 (0.38 – 1.86)
Any test 1.4 (1.01 – 1.95) 1.23 (0.87 – 1.74) 1.17 (0.81 – 1.68)
MNA, Mini Nutritional Assessment; GDS, Geriatric Depression Scale; TUG, Timed 
Up and Go; MMSE, Mini-Mental State Examination; ADL, Activities of Daily Living Scale; 
any test, impairment in at least one test; CKD, chronic kidney disease; CI, confidence 
interval. a Adjusted for sex and age. b Adjusted for sex, age, BMI, morbidity index, vitamin 
D deficiency and current smoking status. Statistically significant results (p < 0.05) were 
highlighted (boldface).
 Table 5. Logistic regression results for 
mild-to-moderate CKD (reference 
category: eGFR ≥60 mL/min/1.73 m2) as 
predictor of impairments in different 
assessment instruments
 König et al.
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to hold advantages as a biomarker for geriatric outcomes 
like impaired gait performance and physical impairment, 
and also frailty  [34, 35] , whereas, when creatinine is used 
to estimate GFR, findings are more inconsistent.
 A comprehensive review of mechanisms linking GFR 
decline to physical impairment, and gait performance in 
particular, is beyond the scope of this paper; anyway, 
there is growing evidence that muscle impairment (im-
paired muscle metabolism, sarcopenia) represents an im-
portant intermediate step in the causal chain  [36] .
 Furthermore, we could not show a significant associa-
tion of CKD G3a with cognitive impairment, as assessed 
by the MMSE. It should be noted, however, that the 
MMSE lacks sensitivity to detect mild cognitive impair-
ment, particularly among those with higher educational 
attainment as in this study  [17, 37] . Accordingly, the 
number of participants with cognitive impairment 
(MMSE  ≤ 24/30) was particularly small in the BASE-II 
cohort ( Table 4 ). Moreover, previous studies have like-
wise provided conflicting results as to the relationship be-
tween cognitive impairment and early-stage CKD. Some 
studies have indeed reported positive associations be-
tween mild-to-moderately reduced levels of kidney func-
tion and cognitive impairment  [11, 38, 39] , whereas oth-
ers have not  [40, 41] . For example, Kurella et al.  [42] dem-
onstrated a significant positive association between 
impaired cognition and severe CKD, but not mild-to-
moderate CKD.
 Regarding depression, it has been repeatedly shown 
that depression is common and underrecognized in pa-
tients with advanced CKD or end-stage-renal disease 
 [43] . Whether or not less severe forms of impaired kidney 
function (eGFR  ≥ 30 or even  ≥ 45 mL/min/1.73 m 2 ) are 
associated with more depressive symptoms compared to 
preserved kidney function (eGFR  ≥ 60 mL/min/1.73 m 2 ) 
is still unclear. In line with our results, Ricardo et al.  [41, 
44] could not establish an association of early-stage CKD 
with depression. In contrast, Heeres et al.  [45] recently 
showed that an increase in depressive symptoms was al-
ready present in patients with eGFR <60 mL/min/1.73 
m 2 , compared to those with a better eGFR  [45] . Whereas 
the implications of marginal uremia at a GFR of 45–59 
mL/min/1.73 m 2 are unclear anyway, it appears plausible, 
that, given individuals affected by mild-to-moderate 
CKD do not even notice or know they have a kidney prob-
lem, and that functional status and cognition are also 
largely preserved, this may not pose a challenge for men-
tal health.
 At last, it is well known that advanced CKD leads to a 
state of metabolic and nutritional derangements, referred 
to as protein energy wasting or anorexia in CKD, and at-
tributed to the retention of uremic toxins, intercurrent 
illness, inflammation, and comorbid diseases  [46] . How-
ever, there are currently no data linking mild-to-moder-
ate CKD and nutrition. Likewise, our results do not sug-
gest an increased nutritional risk with CKD G3a.
 In view of the ongoing debate, whether older adults 
with an eGFR of 45–59 mL/min/1.73 m 2 should be la-
beled with “CKD,” or rather manifest physiological age-
related GFR decline  [3, 7, 8] , our results and the above-
mentioned findings of others are valuable, although they 
do not allow for a clear position yet. Admittedly, in the 
present study the relative differences in geriatric condi-
tions comparing individuals with CKD G3a and individ-
uals with preserved kidney function were rather margin-
al. Anyway, in about one-fifth of individuals (21 and 
15.9%, with and without CKD G3a, respectively), we 
identified one or more geriatric conditions by performing 
a GA. Identifying these conditions is essential to prevent 
or delay their complications, and may lead to better health 
outcomes.
 The strengths of our study include the comprehensive 
characterization of the BASE-II cohort. To our knowl-
edge, this is the first study investigating the relationship 
between mild-to-moderately decreased GFR (CKD G3a) 
and the outcomes of a broad GA in large a cohort of com-
munity-dwelling older adults. Whereas most previous 
studies often have only examined one domain in relation 
to kidney function, we were able to consider a set of 6 
commonly used instruments previously recommended to 
be used in older adults with CKD  [15] .
 Since cystatin C was not available in BASE-II, which is 
a limitation, we chose to use the novel FAS equation to 
estimate kidney function, which has been demonstrated 
to be very sensitive and accurate in the elderly with the 
extra advantage of being applicable across the whole age 
spectrum  [26] , as the otherwise recommended CKD-EPI 
equation has been consistently shown to overestimate 
GFR in older adults  [4] . Moreover, in contrast to other 
studies, we excluded subjects with eGFR <45 mL/min/1.73 
m 2 from our analyses. Accordingly, our CKD group had 
effectively “mild-to-moderate” CKD. Furthermore, it has 
to be pointed out that extra-trained physicians surveyed 
the complete GA implemented in this study, whereas 
most previous studies used, for example, questionnaires 
or telephone interviews for data acquisition.
 Some limitations of the present study have to be ad-
dressed. First, diagnosis of CKD was based on single time 
point measurements of creatinine and albuminuria. Due 
to the cross-sectional design, conclusions regarding cau-
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sality and direction of causality are limited. Moreover, 
since BASE-II participants were well functioning, edu-
cated above average and had a relatively small disease 
burden  [17, 18] , our results should be interpreted with 
caution with respect to their validity for the general pop-
ulation. Also, our results may not be generalized to non-
Caucasian populations.
 Conclusion 
 To conclude, altogether, our GA identified one or 
more impairments in the domains functional status, gait, 
cognition, mood, and nutrition, in 21% of participants 
with mild-to-moderate CKD, and 15.9% of participants 
with preserved kidney function. After adjusting for co-
variates, only a positive association between mild-to-
moderate CKD and impaired gait performance (TUG) 
remained statistically significant. Given the high preva-
lence of early-stage CKD in older adults, improved un-
derstanding of the associated implications on geriatric 
conditions is essential to improve health outcomes. 
Therefore, further studies are warranted to clarify the val-
ue of GA in the management of early-stage CKD.
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